Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tipifarnib with Chemoradiation for Locally Advanced Pancreatic Cancer
NCT00026104Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Nov 2001
- Primary completion
- Aug 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tipifarnib in pancreatic cancer (PC) (2 arms), sponsored by National Cancer Institute. Primary endpoint: Overall Survival at 1 year. Started Nov 2001; status: completed.
02
Drugs
tipifarnib
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT00026104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00026104.